Relevant bibliographies by topics / ABN / Journal articles

Journal articles on the topic 'ABN'

To see the other types of publications on this topic, follow the link: ABN.
Author: Grafiati
Published: 4 June 2021
Last updated: 2 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'ABN.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Talbot, Kevin, and Joanne Lawrence. "ABN news." Practical Neurology 16, no. 1 (January 14, 2016): 81. http://dx.doi.org/10.1136/practneurol-2015-001359.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Talbot, Kevin, and Joanne Lawrence. "ABN news." Practical Neurology 16, no. 2 (March 15, 2016): 171. http://dx.doi.org/10.1136/practneurol-2016-001402.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Talbot, Kevin, and Joanne Lawrence. "ABN news." Practical Neurology 16, no. 3 (May 13, 2016): 252. http://dx.doi.org/10.1136/practneurol-2016-001439.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Burn, David J., and Joanne Lawrence. "ABN news." Practical Neurology 16, no. 4 (July 14, 2016): 338. http://dx.doi.org/10.1136/practneurol-2016-001462.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Burn, David J., and Joanne Lawrence. "ABN news." Practical Neurology 16, no. 5 (September 13, 2016): 424. http://dx.doi.org/10.1136/practneurol-2016-001496.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Burn, David J., and Joanne Lawrence. "ABN News." Practical Neurology 16, no. 6 (November 15, 2016): 504. http://dx.doi.org/10.1136/practneurol-2016-001537.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lawrence, Joanne, and David J. Burn. "ABN News." Practical Neurology 17, no. 1 (January 17, 2017): 84. http://dx.doi.org/10.1136/practneurol-2016-001586.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lawrence, Joanne, and David J. Burn. "ABN News." Practical Neurology 17, no. 2 (March 18, 2017): 170. http://dx.doi.org/10.1136/practneurol-2017-001641.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Nicholl, David, and Joanne Lawrence. "ABN news." Practical Neurology 17, no. 4 (July 13, 2017): 334. http://dx.doi.org/10.1136/practneurol-2017-001741.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lawrence, Joanne, and David Joseph Nicholl. "ABN News." Practical Neurology 17, no. 5 (September 19, 2017): 421. http://dx.doi.org/10.1136/practneurol-2017-001774.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Lawrence, Joanne, and David Joseph Nicholl. "ABN News." Practical Neurology 17, no. 6 (November 15, 2017): 502. http://dx.doi.org/10.1136/practneurol-2017-001825.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Lawrence, Joanne, David Joseph Nicholl, and Catherine Mummery. "ABN News." Practical Neurology 18, no. 1 (January 16, 2018): 80. http://dx.doi.org/10.1136/practneurol-2017-001868.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Lawrence, Joanne, and David Joseph Nicholl. "ABN News." Practical Neurology 18, no. 2 (March 27, 2018): 174. http://dx.doi.org/10.1136/practneurol-2018-001928.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Lawrence, Joanne, and David Joseph Nicholl. "ABN news." Practical Neurology 18, no. 3 (May 18, 2018): 260. http://dx.doi.org/10.1136/practneurol-2018-001992.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Lawrence, Joanne, and David Joseph Nicholl. "ABN News." Practical Neurology 18, no. 5 (September 17, 2018): 432. http://dx.doi.org/10.1136/practneurol-2018-002080.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Lawrence, Joanne, and David Joseph Nicholl. "ABN news." Practical Neurology 19, no. 5 (October 2019): 460. http://dx.doi.org/10.1136/practneurol-2019-002390.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Lawrence, Joanne, and Jon Sussman. "ABN News." Practical Neurology 19, no. 6 (November 15, 2019): 554. http://dx.doi.org/10.1136/practneurol-2019-002449.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Lawrence, Joanne, and Jon Sussman. "ABN news." Practical Neurology 20, no. 2 (March 17, 2020): 183. http://dx.doi.org/10.1136/practneurol-2020-002542.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Lawrence, Joanne, and Jon Sussman. "ABN News." Practical Neurology 20, no. 3 (May 2020): 270. http://dx.doi.org/10.1136/practneurol-2020-002608.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Lawrence, Joanne, and Jon Sussman. "ABN news." Practical Neurology 20, no. 4 (July 17, 2020): 349. http://dx.doi.org/10.1136/practneurol-2020-002689.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Lawrence, Joanne, and Jon Sussman. "ABN news." Practical Neurology 20, no. 5 (September 21, 2020): 435. http://dx.doi.org/10.1136/practneurol-2020-002771.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Lawrence, Joanne, and Jon Sussman. "ABN news." Practical Neurology 20, no. 6 (November 23, 2020): 521. http://dx.doi.org/10.1136/practneurol-2020-002847.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Lawrence, Joanne, and Jon Sussman. "ABN news." Practical Neurology 21, no. 2 (March 16, 2021): 181. http://dx.doi.org/10.1136/practneurol-2021-002970.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Lawrence, Joanne, Jon Sussman, and Martin R. Turner. "ABN news." Practical Neurology 21, no. 3 (May 17, 2021): 271. http://dx.doi.org/10.1136/practneurol-2021-003062.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Lawrence, Joanne, and Jon Sussman. "ABN news." Practical Neurology 21, no. 4 (July 23, 2021): 372. http://dx.doi.org/10.1136/practneurol-2021-003130.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Lawrence, Joanne, and Jon Sussman. "ABN news." Practical Neurology 21, no. 5 (September 17, 2021): 462. http://dx.doi.org/10.1136/practneurol-2021-003185.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Kuhn, D. T., and G. Packert. "Paternal imprinting of inversion Uab1 causes homeotic transformations in Drosophila." Genetics 118, no. 1 (January 1, 1988): 103–7. http://dx.doi.org/10.1093/genetics/118.1.103.

Full text
Abstract:
Abstract Paternal transmission of the bithorax-complex (BX-C) rearrangement, inversion Uab1, causes a specific dominant gain of function phenotype in most abdominal segments. This represents a case of paternal imprinting since the mutant phenotype will occur only if inversion Uab1 is paternally transmitted. The transformations in males are toward genital arch tissue. For females the transformations are to tissue found on abdominal segment 7 (Ab7) and to structures normally restricted to the genital disc. Ninety-six percent of transformed areas appear on Ab5 and Ab6 in both sexes and on Ab7 in females, coinciding with the Abd-B domain. Four percent of the transformations occurred on Ab1 through Ab4, coinciding with the abd-A domain. The mutant phenotype can be dramatically enhanced by modifying genes such as the posterior BX-C mutant tuh-3. Expressivity is modulated by maternal effect alleles interacting with tuh-3. A region of function within inversion Uab1 appears to be programmed during spermatogenesis to function in a legacy dependent manner during embryogenesis.
APA, Harvard, Vancouver, ISO, and other styles
28

Phan, Thanh Nam, Okwha Kim, Manh Tuan Ha, Cheol Hwangbo, Byung-Sun Min, and Jeong-Hyung Lee. "Albanol B from Mulberries Exerts Anti-Cancer Effect through Mitochondria ROS Production in Lung Cancer Cells and Suppresses In Vivo Tumor Growth." International Journal of Molecular Sciences 21, no. 24 (December 14, 2020): 9502. http://dx.doi.org/10.3390/ijms21249502.

Full text
Abstract:
Albanol B (ABN-B), an arylbenzofuran derivative isolated from mulberries, has been shown to have anti-Alzheimer’s disease, anti-bacterial and antioxidant activities. The aim of this study was to investigate the anti-cancer effect of this compound against lung cancer cells. The results show that ABN-B inhibited the proliferation of four human lung cancer cell lines (A549, BZR, H1975, and H226) and induced apoptosis, based on the cleavage of caspase-7 and PARP (poly (ADP-ribose) polymerase), as well as the downregulation of Bcl-2. ABN-B also induced cell cycle arrest at G2/M by down-regulating the expression of CKD1 (cyclin-dependent kinase 1) and cyclin B1, but up-regulating p21 (cyclin-dependent kinase inhibitor 1) expression. Notably, ABN-B increased the production of mitochondrial reactive oxygen species (ROS); however, treatment with mito-TEMPO (a specific mitochondrial antioxidant) blocked ABN-B-induced cell cycle arrest at G2/M and apoptosis, as well as the up-regulation of p21 and down-regulation of CDK1 and cyclin B1 induced by ABN-B. At the molecular level, ABN-B-induced mitochondrial ROS production increased the phosphorylation levels of AKT (protein kinase B) and ERK1/2 (extracellular signal-regulated kinase 1/2), while the inhibition of these kinases blocked the ABN-B-induced up-regulation of p21 and down-regulation of CDK1 and cyclin B1. Moreover, ABN-B significantly suppressed tumor growth in Ex-3LL (Lewis lung carcinoma) tumor-bearing mice. Taken together, these results suggest that ABN-B can exert an anti-cancer effect by inducing apoptosis and cell cycle arrest at G2/M through mitochondrial ROS production in lung cancer cells.
APA, Harvard, Vancouver, ISO, and other styles
29

Cardinal von Widdern, Julian, Tim Hohmann, and Faramarz Dehghani. "Abnormal Cannabidiol Affects Production of Pro-Inflammatory Mediators and Astrocyte Wound Closure in Primary Astrocytic-Microglial Cocultures." Molecules 25, no. 3 (January 23, 2020): 496. http://dx.doi.org/10.3390/molecules25030496.

Full text
Abstract:
Abnormal cannabidiol (abn-CBD) exerts neuroprotective effects in vivo and in vitro. In the present study, we investigated the impact of abn-CBD on the glial production of proinflammatory mediators and scar formation within in vitro models. Primary astrocytic-microglial cocultures and astrocytic cultures from neonatal C57BL/6 mice and CB2 receptor knockout mice were stimulated with lipopolysaccharide (LPS), and the concentrations of tumor necrosis factor α (TNFα), interleukin-6 (IL-6) and nitrite were determined. Furthermore, we performed a live cell microscopy-based scratch-wound assay. After LPS stimulation, TNFα, IL-6 and nitrite production was more strongly increased in cocultures than in isolated astrocytes. Abn-CBD treatment attenuated the LPS-induced production of TNFα and nitrite in cocultures, while IL-6 production remained unaltered. In isolated astrocytes, only LPS-induced TNFα production was reduced by abn-CBD. Similar effects were observed after abn-CBD application in cocultures of CB2 knockout mice. Interestingly, LPS-induced TNFα and nitrite levels were far lower in CB2 knockout cultures compared to wildtypes, while IL-6 levels did not differ. In the scratch-wound assay, treatment with abn-CBD decelerated wound closure when microglial cells were present. Our data shows a differential role of abn-CBD for modulation of glial inflammation and astrocytic scar formation. These findings provide new explanations for mechanisms behind the neuroprotective potential of abn-CBD.
APA, Harvard, Vancouver, ISO, and other styles
30

Topor, Dan Ioan, Sorinel Capusneanu, Dana Maria Constantin, Cristian Marian Barbu, and Ileana Sorina Rakos. "ABB-ABC-ABE-ABM Approach for Implementation in the Economic Entities from Energy Industry." Business and Management Horizons 5, no. 2 (November 20, 2017): 36. http://dx.doi.org/10.5296/bmh.v5i2.12169.

Full text
Abstract:
The purpose of this article lies in demonstrating the effectiveness of four connection methods ABB-ABC-ABE-ABM conducive to successful implementation and improving the performance of an economic entity. The objectives of this study are focused on: (1) the application of ABB-ABC-ABE-ABM within an economic entity within the energetic industry and (2) highlighting performances, including environmental performance. In the framework of this article the contributions are brought by the mix of methods on the national and international level, namely the modalities and stages of their specific within an economic entity. Environmental components are addressed within the mix of economic entity methods used, their benefits and limitations. Based on case study prepared by the authors, the results of applied methods mix to improve environmental performance within the surveyed entity are presented. The article ends with the conclusions of the authors related to the efficiency of the use of the ABB-ABM-ABC-ABE for improving performance, including environmental performance within the surveyed entity.
APA, Harvard, Vancouver, ISO, and other styles
31

Wierda, William G., S. O’Brien, S. Faderl, A. Ferrajoli, G. Garcia-Manero, J. Burger, E. Schlette, L. Abruzzo, S. Lerner, and M. Keating. "Complex Karyotypic Abnormalities Detected by Conventional Cytogenetic Analysis More Strongly Predict Survival Than FISH, ZAP70, or IgVH Mutation Status for Previously Treated Patients with CLL." Blood 110, no. 11 (November 16, 2007): 2065. http://dx.doi.org/10.1182/blood.v110.11.2065.2065.

Full text
Abstract:
Abstract Recently, several novel prognostic factors have been identified; their significance has been demonstrated in selected patient (pt) populations and retrospective analyses. As a group, previously treated pts with CLL likely have their respective, relevant prognostic factors for clinical endpoints, which may be further impacted by treatment (Rx). We prospectively evaluated the significance of newer prognostic factors: FISH abnormalities (abn) (Vysis CLL panel), IgVH mutation status, ZAP70 expression (flow & immunohistochemistry), CD38 expression (≥30%); as well as traditional factors: conventional cytogenetic analysis perfomed on bone marrow metaphases, age, sex, # prior Rx, refractoriness to alkylating agents (ALK) or fludarabine (FLU), absolute lymphocyte count (ALC), HGB, PLT, β-2 microglobulin (B2M), ALB, LDH, creatinine, and Alk Phos as independent predictors for survival in previously treated pts. The group included 473 previously treated pts seen at M.D.Anderson (10/03–8/07), who were evaluated by bone marrow sampling with conventional and FISH cytogenetic analyses, and the new and traditional prognostic factors described above. The median (range) age was 63yrs(31–87) and # prior Rx was 2(1–13). Other characteristics were: 43% Rai high-risk; 35% FLU-refractory; and 39% ALK-refractory; 74% unmutated IgVH; 54% ZAP70+ (flow); 76% ZAP70+ (IHC); and 68% CD38+. FISH results were: 22% del 17p13, 21% del 11q22, 10% +12, and 48% del 13q14 or no abn by the hierarchical classification. Conventional cytogenetic analysis of bone marrow metaphases demonstrated 25% with a complex karyotypic abn (>1 cell with >1 chromosome abn), 58% diploid, 17% with single clonal abn (>1 cell with 1 abn). Of the 100 pts with complex karyotypic abn, 50% had del 17p13, 28% del 11q22, 6% +12, 9% del 13q14, and 7% had no abn by FISH. Survival was measured from the time of prognostic factor characterization (FISH). The median follow-up time was 10mo(0–47). Univariate analyses identified the following significant (p≤.01) predictors for shorter survival: advanced age, # prior Rx, Rai high-risk, ALK- or FLU-refractory, FISH del 17p13; complex karyotypic abn (Figure 1), unmutated IgVH, high ALC, low HGB, low PLT, high B2M, low ALB, high LDH, and high Alk Phos. Multivariate analysis produced the following model with the following significant (p<.05) independent predictors for survival: ALK- (HR 2.2) or FLU-refractory (1.9), complex karyotypic abn (HR 1.8), PLT (HR 0.99), and ALB (HR 0.35). We previously reported complex karyotypic abn as a significant independent predictor for shorter survival in previously treated patients receiving chemoimmunotherapy (JCO23:4070, 2005). These data indicate that for previously treated pts with CLL, a complex karyotypic abn detected by conventional cytogenetic analysis is a strong independent predictor for survival and appears superior to FISH, and other newer prognostic factors such as IgVH mutation status and ZAP70 expression. Figure Figure
APA, Harvard, Vancouver, ISO, and other styles
32

Whitehead, Derek. "ABN and Serials Rationalisation." Australian & New Zealand Journal of Serials Librarianship 1, no. 3 (November 29, 1990): 19–32. http://dx.doi.org/10.1300/j252v01n03_02.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Lawrence, Joanne, and David Joseph Nicholl. "ABN News Feb 2019." Practical Neurology 19, no. 1 (January 17, 2019): 86. http://dx.doi.org/10.1136/practneurol-2018-002173.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Lawrence, Joanne, and David Joseph Nicholl. "ABN News April 2019." Practical Neurology 19, no. 2 (March 14, 2019): 182. http://dx.doi.org/10.1136/practneurol-2019-002242.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Lawrence, Joanne, and David Joseph Nicholl. "ABN News June 2019." Practical Neurology 19, no. 3 (May 21, 2019): 275. http://dx.doi.org/10.1136/practneurol-2019-002306.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Lawrence, Joanne, and David Joseph Nicholl. "ABN news August 2019." Practical Neurology 19, no. 4 (July 11, 2019): 373. http://dx.doi.org/10.1136/practneurol-2019-002355.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Yamaguchi, Asako, Yuri Sogabe, Satomi Fukuoka, Takuo Sakai, and Toshiji Tada. "Structures of endo-1,5-α-L-arabinanase mutants fromBacillus thermodenitrificansTS-3 in complex with arabino-oligosaccharides." Acta Crystallographica Section F Structural Biology Communications 74, no. 12 (November 26, 2018): 774–80. http://dx.doi.org/10.1107/s2053230x18015947.

Full text
Abstract:
The thermostable endo-1,5-α-L-arabinanase fromBacillus thermodenitrificansTS-3 (ABN-TS) hydrolyzes the α-1,5-L-arabinofuranoside linkages of arabinan. In this study, the crystal structures of inactive ABN-TS mutants, D27A and D147N, were determined in complex with arabino-oligosaccharides. The crystal structures revealed that ABN-TS has at least six subsites in the deep V-shaped cleft formed across one face of the propeller structure. The structural features indicate that substrate recognition is profoundly influenced by the remote subsites as well as by the subsites surrounding the active center. The `open' structure of the substrate-binding cleft of the endo-acting ABN-TS is suitable for the random binding of several sugar units in polymeric substrates.
APA, Harvard, Vancouver, ISO, and other styles
38

Masarova, Lucia, Prithviraj Bose, Naval G. Daver, Naveen Pemmaraju, Kate J. Newberry, Jorge E. Cortes, Hagop M. Kantarjian, and Srdan Verstovsek. "Cytogenetic Risk Stratification in Primary Versus Post-Essential Thrombocythemia / Post-Polycythemia Vera Myelofibrosis." Blood 128, no. 22 (December 2, 2016): 4250. http://dx.doi.org/10.1182/blood.v128.22.4250.4250.

Full text
Abstract:
Abstract Introduction: The Dynamic International Prognostic Scoring System-Plus (DIPPS-Plus) for primary myelofibrosis (PMF) categorizes cytogenetic abnormalities as "favorable" and "unfavorable." Abnormalities (Abn) -7/7q-; -5/5q-; i(17q), +8; inv(3); 12p-; 11q23; and complex karyotype (CK; >3 Abn) are considered unfavorable. More recently monosomal karyotype (MK), defined as 2 autosomal monosomies or a single monosomy with at least one additional structural Abn, was also recognized as unfavorable (Vaidya, Blood 2011). While the prognostic impact of cytogenetic Abn has been studied in patients with PMF, almost no data exist in patients with post-essential thrombocythemia/polycythemia vera myelofibrosis (PET/PV-MF). Objective: To identify the impact of cytogenetic Abn on prognosis in patients with PMF and PET/PPV-MF referred to our center between 1984 and 2013. Methods: We retrospectively reviewed the charts of 1100 patients with MF. Cytogenetic analysis performed at the time of referral to our institution was reported according to the International System for Human Cytogenetic Nomenclature. Overall survival (OS) was calculated and compared using the Kaplan-Meier method with the log rank test. The impact of each cytogenetic Abn on OS was measured by stepwise Cox regression model by comparing them against patients with diploid karyotype. Analyses were conducted separately for patients with PMF and PET/PPV-MF. Results: Cytogenetic data (≥ 10 metaphases) were available in 981 patients (660 with PMF and 321 with PET/PPV-MF). Median age was similar in both groups (66 years; range, 27-90), and 61% of patients were male. The distribution of DIPSS scores were similar in both groups (overall 7% low, 37% int-1, 41% int-2 and 15% high). OS in each DIPSS category were 134, 65, 33, 19 months in patients with PMF; and 160, 73, 48, 36 in patients with PET/PPV-MF (in both groups P<0.001). The JAK2 mutation was present in 65% of patients in both groups. Overall, 621 (63%) patients had diploid karyotype (DK), 17% had CK (n=62), and 7% had MK (n=26). Abnormal karyotypes present in >10% of patients were single 20q- (n=75, 21%), single 13q- (n=38, 11%), and CK (n=62, 17%). Others Abn (single +8, +9, single -7/7q-, -5/5q-, or various combinations of the two Abn) occurred less frequently. Importantly, Abn of chromosome (chr) 17 occurred only in patients with PMF, while all other Abn were similarly distributed among PMF and PET/PPV-MF. Ninety nine patients (10%) developed AML, 44% of whom had cytogenetic Abn, similar in PMF and PET/PPV-MF. After a median follow-up of 31 months (range, 0.5-251), 548 (56%) of patients have died, with similar rates in both groups. Impact of different cytogenetic Abn on OS is presented in Table 1 and Graph 1 for PMF, and Graph 2 for PET/PPV-MF. We have identified 4 different risk categories in PMF patients with respective median OS of 86, 46, 14 and 6 months (P<0.001, Graph 1A). Only 2 different categories were identified in patients with PET/PPV-MF, with the corresponding OS of 70 and 14 months (P<0.001, Graph 1B); further separation of these patients was not possible due to smaller number of patients with specific Abn. Conclusions: Results from our cohort of 691 PMF and 321 PET/PPV-MF patients differ from those described in DIPSS-Plus. First, we showed that OS in patients with PMF and single +8 Abn, and 1-3 abnormalities (excluding chromosomes 5, 7, 12p and MK) is no different than in those with normal karyotype. Second, OS was the best in patients with single 20q- Abn, which was significantly better than in patients with normal karyotype. Third, we report cytogenetic stratification on the largest cohort of PET/PPV-MF patients, with findings different than in PMF (Table 1). Further validation in larger multicenter studies is warranted. Table Table. Figure Overall survival in PMF [1A] and PET/PPV-MF [1B] patients stratified by cytogenetic groups. Figure. Overall survival in PMF [1A] and PET/PPV-MF [1B] patients stratified by cytogenetic groups. Disclosures Cortes: ARIAD: Consultancy, Research Funding; BMS: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Teva: Research Funding.
APA, Harvard, Vancouver, ISO, and other styles
39

Takao, Makoto, Kana Akiyama, and Takuo Sakai. "Purification and Characterization of Thermostable Endo-1,5-α-l-Arabinase from a Strain of Bacillus thermodenitrificans." Applied and Environmental Microbiology 68, no. 4 (April 2002): 1639–46. http://dx.doi.org/10.1128/aem.68.4.1639-1646.2002.

Full text
Abstract:
ABSTRACT A strain of a thermophilic bacterium, tentatively designated Bacillus thermodenitrificans TS-3, with arabinan-degrading activity was isolated. It produced an endo-arabinase (ABN) (EC 3.2.1.99) and two arabinofuranosidases (EC 3.2.1.55) extracellularly when grown at 60°C on a medium containing sugar beet arabinan. The ABN (tentatively called an ABN-TS) was purified 7,417-fold by anion-exchange, hydrophobic, size exclusion, and hydroxyapatite chromatographies. The molecular mass of ABN-TS was 35 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and the isoelectric point was pH 4.5. The enzyme was observed to be more thermostable than known ABNs; it had a half-life of 4 h at 75°C. The enzyme had optimal activity at 70°C and pH 6.0. The enzyme had apparent Km values of 8.5 and 45 mg/ml and apparent V max values of 1.6 and 1.1 mmol/min/mg of protein against debranched arabinan (α-1,5-arabinan) and arabinan, respectively. The enzyme had no pectin-releasing activity (protopectinase activity) from sugar beet protopectin, differing from an ABN (protopectinase-C) from mesophilic Bacillus subtilis IFO 3134. The pattern of degradation of debranched arabinan by ABN-TS indicated that the enzyme was an endo-acting enzyme and the main end products were arabinobiose and arabinose. The results of preliminary experiments indicated that the culture filtrate of strain TS-3 is suitable for l-arabinose production from sugar beet pulp at high temperature.
APA, Harvard, Vancouver, ISO, and other styles
40

Su, Kai-Han, Cherng-Yuh Su, Po-Wei Chi, Prem Chandan, Cheng-Ta Cho, Wan-Yu Chi, and Maw-Kuen Wu. "Generation of Self-Assembled 3D Network in TPU by Insertion of Al2O3/h-BN Hybrid for Thermal Conductivity Enhancement." Materials 14, no. 2 (January 6, 2021): 238. http://dx.doi.org/10.3390/ma14020238.

Full text
Abstract:
Thermal management has become one of the crucial factors in designing electronic equipment and therefore creating composites with high thermal conductivity is necessary. In this work, a new insight on hybrid filler strategy is proposed to enhance the thermal conductivity in Thermoplastic polyurethanes (TPU). Firstly, spherical aluminium oxide/hexagonal boron nitride (ABN) functional hybrid fillers are synthesized by the spray drying process. Then, ABN/TPU thermally conductive composite material is produced by melt mixing and hot pressing. Then, ABN/TPU thermally conductive composite material is produced by melt mixing and hot pressing. Our results demonstrate that the incorporation of spherical hybrid ABN filler assists in the formation of a three-dimensional continuous heat conduction structure that enhances the thermal conductivity of the neat thermoplastic TPU matrix. Hence, we present a valuable method for preparing the thermal interface materials (TIMs) with high thermal conductivity, and this method can also be applied to large-scale manufacturing.
APA, Harvard, Vancouver, ISO, and other styles
41

Hurowitz, Victor Avigdor. "abN mshkhyt: A New Interpretation." Journal of Biblical Literature 118, no. 2 (1999): 201. http://dx.doi.org/10.2307/3268003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Curreli, L., A. D. Palmas, G. Latte, A. Murgia, and A. Gabbas. "Avascular necrosis of the jaw in multiple myeloma (MM) patients (pts) treated with bisphosphonates (BP)." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 18538. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.18538.

Full text
Abstract:
18538 Background: Oral cavity avascular bone necrosis (ABN) has been recently reported as an emerging serious complication in pts receiving BP for the treatment of hypercalcemia related to MM or metastatic solid tumors. Methods: We report the cases of 6 pts with MM treated initially with pamidronate and later with zoledronic acid (ZA). Results: Pts characteristics : M/F 3/3; mean age 58.4 (46–78); 4 IgG κ,1 γ and 1 κ MM; 5 St IIIA and 1 IIIB; mean history of disease 61.3 mo. (23–103); 5 pts had a relapsing MM refractory to several lines of therapy but 1 pt had received only high dose dexametazone (D); 2 pts had received autologous stem cell transplantation and 1 pt allogenic bone marrow transplantation; mean n.° of BP doses was 41.3 (17–81). At the time of ABN onset all pts were receiving ZA along with, respectively: D (2 pts); cyclophosphamide plus D (1 pt), bortezomib plus D (2 pts) and oral melphalan (1 pt). ABN was localized in 2 pts at alveolar bone of the right maxilla and presented as an inflammation of the gum, followed by a painful bone exposure. In the other 4 pts ABN was localized at mandible and presented as dental abscesses followed in 2/4 pts by cutaneous fistulization. Treatment has included in all pts discontinuation of ZA, antibiotics, chlorhexidine mouthwashes, pain control, minor regional débridement, and bone trimming. In 1 pt a more aggressive surgical approach was attempted at an other Institution and postoperative course was complicated by massive haemorrhage and complete loss of chewing. Four pts dead with progressive disease with a mean overall survival after ABN presentation of 6 mo.; 2 pts are alive after 3 and 4 mo. after ABN presentation; however in all pts ABN significantly worsened quality of life. Conclusions: Oral cavity ABN is a severe complication in refractory MM pts receiving BP. Mechanisms of action of BP that determine a reduction in osteoclastic activity and an accumulation of nonvital osteocytes with microfractures of old mineral matrix appear to play an important role. However other causes may be involved as a long history of disease; an uncontrolled progressive disease; type and doses of previous and present therapies, primarily steroids; status of oral cavity and teeth of pts and possibly the n.° of doses of BP. No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
43

Aragón, Estíbaliz, Cándida Delagado, and Esperanza Marchena. "Diferencias de aprendizaje matemático entre los métodos de enseñanza ABN y CBC." Psychology, Society, & Education 9, no. 1 (April 26, 2017): 61. http://dx.doi.org/10.25115/psye.v9i1.462.

Full text
Abstract:
Resumen: Para prevenir dificultades de aprendizaje de las matemáticas es conveniente emplear metodologías de enseñanza que se adapten al nivel y al ritmo de aprendizaje de los alumnos. Uno de estos métodos es el Algoritmo Abierto Basado en Números (ABN) que se caracteriza por ser flexible, transparente y contextualizado. El objetivo principal de este trabajo fue analizar las diferencias existentes en las habilidades matemáticas tempranas evaluadas mediante el TEMT-i entre alumnos instruidos con ABN (n=68) y enseñanza tradicional (n=54). Los resultados muestran diferencias en las ganancias en los distintos componentes evaluados, siendo significativas a favor del grupo experimental en el subtest relacional, y en las habilidades numéricas de estimación y conocimiento general de los números. Differences in mathematical learning between ABN and CBC teaching methods Abstract: To prevent difficulties in learning mathematics is appropriate to use teaching methods that methods that fit the level and rhythm of student learning. One of these methods is the Open Algorithm Based on Numbers (ABN) which is characterized by flexibility, transparency and contextualization. The main objective of this study was to analyze the differences in early math skills assessed by TEMTt-i between students trained with ABN (n = 68) and traditional teaching (n = 54). The results show gains differences in components assessed, being significant in favor of the experimental group in relational subtest, numerical estimation skills and general knowledge of numbers.
APA, Harvard, Vancouver, ISO, and other styles
44

Lana-Peixoto, Marco Aurélio. "O papel da academia brasileira de neurologia no ensino da neurologia uma visão pessoal." Arquivos de Neuro-Psiquiatria 49, no. 4 (December 1991): 475–79. http://dx.doi.org/10.1590/s0004-282x1991000400020.

Full text
Abstract:
A Academia Brasileira de Neurologia (ABN) tem demonstrado crescente interesse pelo ensino da neurologia, tanto na graduação quanto na residência médica. Ela deve definir o padrão da prática da neurologia no país, traçar o perfil de competência mínima do neurologista, determinar a competência mínima em neurologia do médico não-neurologista, desenvolver suas próprias atividades de ensino, e definir e propiciar o desenvolvimento das qualidades humanísticas desejáveis no neurologista. A ABN deve formular um currículo mínimo de neurologia na graduação e na residência médica e esforçar por sua adoção pelas escolas médicas e pelos Programas de Residência. Além disso, a ABN deve, por si própria, tornar-se agente efetora do ensino através: de um Programa de Educação Continuada, promovendo cursos e simpósios; da elaboração de um sistema de ensino programado em neurologia, via postal; da implantação de videoteca e de banco de dados da literatura. A Comissão de Ensino deve desempenhar papel fundamental em todas as atividades de ensino promovida pela ABN, definindo sua política, estabelecendo prioridades e coordenando as ações de ensino dos Grupos de Trabalho e Pesquisa.
APA, Harvard, Vancouver, ISO, and other styles
45

Houlihan, Diarmaid D., Michael C. Dennedy, and John J. Morrison. "Effects of abnormal cannabidiol on oxytocin-induced myometrial contractility." REPRODUCTION 139, no. 4 (April 2010): 783–88. http://dx.doi.org/10.1530/rep-09-0496.

Full text
Abstract:
The objective of this study was to investigate the effects of abnormal cannabidiol (abn-cbd) on oxytocin-induced myometrial contractility occurring during pregnancy. Isometric tension recordings were performed in isolated myometrial strips from biopsies obtained at elective cesarean section. The effects of cumulative doses of abn-cbd (10−9–10−5 M) on oxytocin-induced myometrial contractions alone, and on those following pre-incubation with SR 144528, AM 251, methylene blue, and iberiotoxin were measured, and dose–response curves were constructed. The pD2(−log EC50) values and the maximal inhibitory (MMI) values that were achieved were compared for each tissue type. Abn-cbd exerted a potent relaxant effect on oxytocin-induced myometrial contractionsin vitro. Pre-incubation with the guanylate cyclase inhibitor, methylene blue, and the BKCachannel antagonist, iberiotoxin, significantly attenuated this effect (for pD2,P<0.01; for MMI,P<0.01). Abn-cbd exerts a potent inhibitory effect on human uterine contractility. This effect is partially mediated through modulation of guanylate cyclase and activation of BKCachannel activity. These findings have implications for physiologic regulation of myometrial quiescence.
APA, Harvard, Vancouver, ISO, and other styles
46

Vergara, Pablo, Deependra Kumar, Sakthivel Srinivasan, Iyo Koyanagi, Toshie Naoi, Sima Singh, and Masanori Sakaguchi. "Remapping of Adult-Born Neuron Activity during Fear Memory Consolidation in Mice." International Journal of Molecular Sciences 22, no. 6 (March 12, 2021): 2874. http://dx.doi.org/10.3390/ijms22062874.

Full text
Abstract:
The mammalian hippocampal dentate gyrus is a unique memory circuit in which a subset of neurons is continuously generated throughout the lifespan. Previous studies have shown that the dentate gyrus neuronal population can hold fear memory traces (i.e., engrams) and that adult-born neurons (ABNs) support this process. However, it is unclear whether ABNs themselves hold fear memory traces. Therefore, we analyzed ABN activity at a population level across a fear conditioning paradigm. We found that fear learning did not recruit a distinct ABN population. In sharp contrast, a completely different ABN population was recruited during fear memory retrieval. We further provide evidence that ABN population activity remaps over time during the consolidation period. These results suggest that ABNs support the establishment of a fear memory trace in a different manner to directly holding the memory. Moreover, this activity remapping process in ABNs may support the segregation of memories formed at different times. These results provide new insight into the role of adult neurogenesis in the mammalian memory system.
APA, Harvard, Vancouver, ISO, and other styles
47

Samjoo, Imtiaz A., Evelyn Worthington, Christopher Drudge, Melody Zhao, Chris Cameron, Dieter A. Häring, Dee Stoneman, Luisa Klotz, and Nicholas Adlard. "Efficacy classification of modern therapies in multiple sclerosis." Journal of Comparative Effectiveness Research 10, no. 6 (April 2021): 495–507. http://dx.doi.org/10.2217/cer-2020-0267.

Full text
Abstract:
Background: The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction. We sought to classify newer therapies (cladribine, ocrelizumab, ofatumumab, ozanimod) based on these guidelines. Materials & methods: Therapies were classified by using direct comparative trial results as per ABN guidelines and generating classification probabilities for each therapy based on comparisons versus placebo in a network meta-analysis for annualized relapse rate. Results: For both approaches, cladribine and ofatumumab were classified as high efficacy. Ocrelizumab and ozanimod (1.0 mg) were classified as moderate or high efficacy depending on the approach used. Conclusion: Cladribine and ofatumumab have an efficacy comparable with therapies classified in the ABN guidelines as high efficacy.
APA, Harvard, Vancouver, ISO, and other styles
48

Cheldieva, F. A., I. G. Kushnareva, V. V. Babak, A. E. Khramov, and T. M. Reshetnyak. "Avascular necrosis in systemic lupus erythematosus: total hip replacement in a patient with mutation in clotting factor V (Leiden) gene, clinical observation." Modern Rheumatology Journal 15, no. 2 (April 23, 2021): 69–76. http://dx.doi.org/10.14412/1996-7012-2021-2-69-76.

Full text
Abstract:
The article provides a description of the systemic lupus erythematosus patient with multiple avascular bone necrosis (ABN), homozygous mutation in clotting factor V (Leiden) gene, who successfully underwent the total hip replacement. The role of high doses of glucocorticoids and coagulation disorders, in particular the homozygous mutation in factor V (Leiden) gene, in the development of ABN is discussed.
APA, Harvard, Vancouver, ISO, and other styles
49

Masarova, Lucia, Prithviraj Bose, Naveen Pemmaraju, Kate J. Newberry, Carlos E. Bueso-Ramos, Jorge E. Cortes, Hagop M. Kantarjian, and Srdan Verstovsek. "Clinical Associations of Cytogenetic Abnormalities in Patients with Primary and Post-Essential Thrombocythemia and Post-Polycythemia Vera Myelofibrosis." Blood 128, no. 22 (December 2, 2016): 4265. http://dx.doi.org/10.1182/blood.v128.22.4265.4265.

Full text
Abstract:
Abstract Introduction: Several studies have evaluated the incidence and clinical relevance of cytogenetic abnormalities in primary myelofibrosis (PMF). However, little is known about the clinical correlation of these abnormalities in patients with post-essential thrombocythemia/polycythemia vera myelofibrosis (PET/PPV-MF). Objective: We aimed to measure the frequency of cytogenetic abnormalities (Abn) and describe their clinical significance in patients with PMF and PET/PPV-MF seen at our center. Methods: We retrospectively reviewed the charts of 1100 patients with MF (766 PMF, 354 PET/PV-MF) who were referred to our institution between 1984 and 2013. Diagnoses were made according to 2008 WHO criteria. Cytogenetic analysis done at the time of referral was reported according to the International System for Human Cytogenetic Nomenclature. Statistical analysis considered parameters at the time of cytogenetic studies. Complex karyotype (CK) was defined as 3 or more unrelated abnormalities (Abn) and monosomal karyotype (MK) was defined as 2 autosomal monosomies or a single monosomy with at least one additional structural abnormality. Fisher's exact, Kruskal-Wallis and Mann-Whitney tests were used for comparisons of categorical and continuous variables, respectively. The Kaplan-Meier analysis with log rank test were used for OS comparisons. Results: Cytogenetic data with > 10 analyzable metaphases were obtained in 981 (89%) patients. Overall, 360 (37%) patients had an abnormal karyotype. Frequency and types of cytogenetic Abn were similar between PMF and PET/PPV-MF (Table 1). Sixty one percent of patients (n=220) had a single Abn, 25% (n=89) had two, and 15% (n=52) had 3 or more Abn, including 6% with MK (n=26). Proportional distribution was similar between PMF and PET/PPV-MF patients. Comparison of patients with one, two, or ≥3 Abn (i.e. CK) revealed that patients with CK were more likely to be anemic (hemoglobin < 10 g/dL, p<0.001) and transfusion dependent (p<0.001) and had higher DIPSS risk scores (p=0.004) than patients with one or two Abn. Among patients with PMF, CK was also associated with thrombocytopenia (p<0.001), while among those with PET/PPV-MF, it was associated with advanced (MF-2, 3) bone marrow fibrosis (p=0.045). Among all patients with one or two Abn, those with Abn in chromosomes 17, 5, or 7 had lower hemoglobin and higher peripheral blood blasts, and were less likely to be JAK2 positive (all p<0.05). Estimated OS was 48 months (range, 43-52) for both patients with PMF and PET/PPV-MF. Among all patients, OS was shorter among those with CK (median 14 months, range 7-21) than in those with one (median 48, range 37-60) or two (median 58, range 43-73) Abn (p=0.000, chi-sq 26.6). Overall median follow up from the time of referral was 29 months (range, 0.5-251) and 61% (n=220) of patients had died. Among all patients, median survival from date of referral was 19 months (range, 0.5-251). During an observation period of 1105 persons-years, progression to AML occurred in 44 (12%) patients after a median time of 13 months (range, 0.5-175). The incidence of AML was higher among those with CK (23% vs 15% vs 13% with CK, two or one Abn, respectively; p=0.014, chi-sq 8.7). Among the known causes of death (in 109 patients), progression of MF/AML was the most common (24%, n=53). Conclusion: The frequency of cytogenetic abnormalities in patients with PMF and PET/PPV-MF and their clinical relevance appear to be similar. Patients with CK have shorter OS and a higher incidence of AML in both PMF and PET/PPV-MF. Table Table. Disclosures Cortes: ARIAD: Consultancy, Research Funding; Bristol-Myers Squib: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Teva: Research Funding.
APA, Harvard, Vancouver, ISO, and other styles
50

Kuendgen, Andrea, Heinz Tuechler, Meritxell Nomdedeu, Detlef Haase, Guillermo Garcia-Manero, Rami S. Komrokji, Francesc Sole, et al. "Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)." Blood 128, no. 22 (December 2, 2016): 112. http://dx.doi.org/10.1182/blood.v128.22.112.112.

Full text
Abstract:
Abstract To develop a prognostic scoring system tailored for therapy-related myelodysplastic syndromes (tMDS), we put together a database containing 1933 patients (pts) with tMDS from Spanish, German, Swiss, Austrian, US, Italian, and Dutch centers diagnosed between 1975-2015. Complete data to calculate the IPSS and IPSS-R were available in 1603 pts. Examining different scoring systems, we found that IPSS and IPSS-R do not risk stratify tMDS as well as they do primary MDS (pMDS), thereby supporting the need for a tMDS-specific score (Kuendgen et al., ASH 2015). The current analysis focuses on cytogenetic information as a potential component of a refined tMDS score, based on this large, unique patient cohort. Of the 1933 pts, 477 had normal karyotype (KT), 197 had missing cytogenetics, while 467 had a karyotype not readily interpretable. Incomplete karyotype descriptions will be reedited for the final evaluation. Of the remaining 1269 pts the most frequent cytogenetic abnormalities (abn) were: -7, del(5q), +mar, +8, del(7q), -5, del(20q), -17, -18, -Y, del(12p), -20, and +1 with >30 cases each. Frequencies are shown in Table 1. Some abn were observed mostly or solely within complex KTs, such as monosomies, except -7. Others, like del(20q) or -Y, are mainly seen as single or double abn, while del(5q), -7, or del(7q) are seen in complex as well as non-complex KTs. The cytogenetic profile overlapped with that of pMDS (most frequent abn: del(5q), -7/del(7q), +8, -18/del(18q), del(20q), -5, -Y, -17/del(17p), +21, and inv(3)/t(3q) (Schanz et al, JCO 2011)), with notable differences including overrepresentation of complete monosomies, a higher frequency of -7 or t(11q23), and a more frequent occurrence of cytogenetic subtypes in complex KTs, which was especially evident in del(5q) occurring as a single abn in 16%, compared to 70% within a complex KT. IPSS-R cytogenetic groups were distributed as follows: Very Good (2%), Good (35%), Int (17%), Poor (15%), Very Poor (32%). Regarding the number of abn (including incomplete KT descriptions) roughly 30% had a normal KT, 20% 1, 10% 2, and 40% ≥3 abn, compared to pMDS: 55% normal KT, 29% 1, 10% 2, and 6% ≥3 abn. To be evaluable for prognostic information, abn should occur in a minimum of 10 pts. As a single aberration this was the case for -7, +8, del(5q), del(20q), del(7q), -Y, and t(11;varia) (q23;varia). Of particular interest, there was no apparent prognostic difference between -7 and del(7q); del(5q) as a single abn was associated with a relatively good survival, while the prognosis was poor with the first additional abn; t(11q23) occurred primarily as a single abn and was associated with an extremely poor prognosis, and prognosis of pts with ≥4 abn was dismal independent of composition (Table 1). To develop a more biologically meaningful scoring system containing homogeneous and prognostically stable groups, we will further combine subgroups with different abn leading to the same cytogenetic consequences. For example, deletions, unbalanced translocations, derivative chromosomes, dicentric chromosomes of 17p, and possibly -17 all lead to a loss of genetic material at the short arm of this respective chromosome affecting TP53. Further information might be derived from analyses of the minimal common deleted regions. For some abn, like del(11q), del(3p), and del(9q), this can be refined to one chromosome band only (table 1). Conclusion: Development of a robust scoring system for all subtypes of tMDS is challenging using existing variables. This focused analysis on the cytogenetic score component shows that favorable KTs are evident in a substantial proportion of pts, in contrast to historic data describing unfavorable cytogenetics in the majority of pts. Although complex and monosomal KTs are overrepresented, this suggests the existence of distinct tMDS-subtypes, although some of these cases might not be truly therapy-induced despite a history of cytotoxic treatment. The next steps will be to analyze the prognosis of the different groups, develop a tMDS cytogenetic score, and examine minimal deleted regions to identify candidate genes for development of tMDS, as well as to describe the possible influence of different primary diseases and treatments (radio- vs chemotherapy, different drugs) on induction of cytogenetic subtypes. Our detailed analysis of tMDS cytogenetics should reveal important prognostic information and is likely to help understand mechanisms of MDS development. Disclosures Komrokji: Novartis: Consultancy, Speakers Bureau; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding. Sole:Celgene: Membership on an entity's Board of Directors or advisory committees. Sekeres:Celgene: Membership on an entity's Board of Directors or advisory committees; Millenium/Takeda: Membership on an entity's Board of Directors or advisory committees. Roboz:Cellectis: Research Funding; Agios, Amgen, Amphivena, Astex, AstraZeneca, Boehringer Ingelheim, Celator, Celgene, Genoptix, Janssen, Juno, MEI Pharma, MedImmune, Novartis, Onconova, Pfizer, Roche/Genentech, Sunesis, Teva: Consultancy. Steensma:Amgen: Consultancy; Genoptix: Consultancy; Janssen: Consultancy; Celgene: Consultancy; Millenium/Takeda: Consultancy; Ariad: Equity Ownership. Schlenk:Pfizer: Honoraria, Research Funding; Amgen: Research Funding. Valent:Amgen: Honoraria; Deciphera Pharmaceuticals: Research Funding; Celgene: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Ariad: Honoraria, Research Funding; Deciphera Pharmaceuticals: Research Funding. Giagounidis:Celgene Corporation: Consultancy. Giagounidis:Celgene Corporation: Consultancy. Platzbecker:Celgene Corporation: Honoraria, Research Funding; TEVA Pharmaceutical Industries: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Janssen-Cilag: Honoraria, Research Funding; Amgen: Honoraria, Research Funding. Lübbert:Janssen-Cilag: Other: Travel Funding, Research Funding; Celgene: Other: Travel Funding; Ratiopharm: Other: Study drug valproic acid.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'ABN' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography